| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors
|
Mies, Anna
|
|
2017
|
54 |
3 |
p. 141-146
|
artikel
|
| 2 |
Individual risk assessment in MDS in the era of genomic medicine
|
Cargo, Catherine
|
|
2017
|
54 |
3 |
p. 133-140
|
artikel
|
| 3 |
Introduction
|
Malcovati, Luca
|
|
2017
|
54 |
3 |
p. 129-132
|
artikel
|
| 4 |
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
|
Talati, Chetasi
|
|
2017
|
54 |
3 |
p. 159-166
|
artikel
|
| 5 |
Masthead
|
|
|
2017
|
54 |
3 |
p. IFC
|
artikel
|
| 6 |
Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes
|
Kröger, Nicolaus
|
|
2017
|
54 |
3 |
p. 154-158
|
artikel
|
| 7 |
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity
|
Madanat, Yazan
|
|
2017
|
54 |
3 |
p. 147-153
|
artikel
|
| 8 |
outside front cover, PMS 8883 metallic AND 4/C
|
|
|
2017
|
54 |
3 |
p. OFC
|
artikel
|
| 9 |
table of contents
|
|
|
2017
|
54 |
3 |
p. A1
|
artikel
|
| 10 |
Therapeutic targeting of RNA splicing in myelodysplasia
|
Kim, Young Joon
|
|
2017
|
54 |
3 |
p. 167-173
|
artikel
|
Tijdschrift beschrijving